Weight loss achieved using an energy restriction diet with normal or higher dietary protein decreased the number of CD14++CD16+ proinflammatory monocytes and plasma lipids and lipoproteins in middle-aged, overweight, and obese adults by Kim, Jung Eun et al.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Weight loss achieved using an energy restriction diet with normal or higher dietary 
protein decreased the number of CD14++CD16+ pro-inflammatory monocytes and 
plasma lipids and lipoproteins in middle-aged, overweight and obese adults 
Jung Eun Kim1, Ge Lin2, Jing Zhou1, Julie Ann Mund3, Jamie Case3,4, Wayne W 
Campbell1 
1 Nutrition Science, Purdue University, West Lafayette, IN, United States 
2 Biochemistry, Purdue University, West Lafayette, IN, United States 
3 Angio BioCore, Melvin and Bren Simon Cancer Center, Indiana University School of 
Medicine, Indianapolis, IN, United States 
4 Scripps Clinic Medical Group, Center for Organ and Cell Transplantation, La Jolla, CA, 
United States 
Address correspondence to: Wayne Campbell, PhD, Department of Nutrition Science, 
Purdue University, 700 West State Street, West Lafayette, IN  47907; phone 765-494-
8236; fax 765-494-0674; email campbellw@purdue.edu 
E-mail address 
Jung Eun Kim: kim1507@purdue.edu 
Ge Lin: gracelin54@gmail.com 
Jing Zhou: zhou151@purdue.edu 
Julie Mund: jmund@iu.edu 
Jamie Case: Case.Jamie@scrippshealth.org 
Wayne W. Campbell: campbellw@purdue.edu 
_________________________________________________________________________________
 
This is the author's manuscript of the article published in final edited form as:
Kim, J. E., Lin, G., Zhou, J., Mund, J. A., Case, J., & Campbell, W. W. (2017). Weight loss achieved using an energy restriction diet with normal or 
higher dietary protein decreased the number of CD14++CD16+ proinflammatory monocytes and plasma lipids and lipoproteins in middle-aged, 
overweight, and obese adults. Nutrition Research, 40, 75–84. https://doi.org/10.1016/j.nutres.2017.02.007
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
2 
 
List of Abbreviations (alphabetical order):  
HP: high protein 
MPFC: multi-parametric flow cytometry 
MNCs: mononuclear cells 
MS: monocyte subpopulations  
NP: normal protein 
TC: total-cholesterol  
TG: triglyceride 
HDL: high density lipoprotein cholesterol  
LDL: low density lipoprotein cholesterol 
UUC: urinary urea nitrogen  
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Abstract: 
Monocytes are involved in immune responses and specific monocyte subpopulations 
(MS) that express intermediate to high levels of CD16 are associated with obesity and 
cardiovascular events. Consuming high protein (HP) when dieting improves body 
composition and cardio-metabolic health outcomes, but whether HP affects MS during 
weight loss remains unknown. We assessed the effect of HP on energy restriction (ER)-
induced changes in MS in overweight and obese adults. The relations between MS and 
plasma lipids and lipoproteins were also examined. We hypothesized that independent 
of protein intake, ER-induced weight loss would decrease the numbers of MS and that 
MS and plasma lipids and lipoproteins would be related. Thirty-two adults (age 52±1y, 
BMI 31.3±0.5kg/m2, means±SE) consumed either a normal protein (n=18) or HP (n=14) 
(0.8 vs. 1.5g•kg-1•d-1 protein) ER diet (750kcal/d deficit) for 16 wk. The HP diet included 
0.7g•kg-1•d-1 of milk protein isolate. Fasting plasma lipids, lipoproteins, and the numbers 
of MS were analyzed. Over time, independent of protein intake, CD14++CD16+ cell 
number decreased, while CD14dimCD16++, CD14+CD16+, and CD14+CD16- cell 
numbers remained unchanged. CD14dimCD16++ cell number was negatively associated 
with total-cholesterol (TC) and triglyceride, while CD14++CD16+ cell number was 
positively associated with TC, low-density lipoprotein cholesterol (LDL), TC to high 
density lipoprotein cholesterol (HDL) ratio, and LDL to HDL ratio. Weight loss achieved 
while consuming an ER diet with either normal or high protein may improve immunity by 
partially decreasing pro-inflammatory monocytes. Associations between MS and plasma 
lipids and lipoproteins are confirmed in overweight and obese adults.   
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1. Introduction 
Obesity is associated with an increased risk of cardio-metabolic diseases including 
cardiovascular disease and type 2 diabetes [1-3]. It is well known that obesity induces 
unfavorable blood plasma lipid and lipoprotein profiles [3] and activation of innate 
immunity [4, 5], resulting in the development of atherosclerosis and insulin resistance. In 
particular, monocytes are involved with the regulation of innate immunity, including 
phagocytosis, secretion of inflammatory cytokines, and production of reactive oxygen 
species [6, 7]. Therefore, there is an emerging research interest to better understand 
how modulating circulating monocytes may impact obesity-induced cardio-metabolic 
diseases. 
Based on the different levels of expression of CD14 and CD16 cell-surface markers 
[8], human blood monocytes display heterogeneous subpopulations [9, 10]. Particularly, 
monocytes that express intermediate to high levels of CD16, also known as CD16+ 
monocytes, are considered pro-inflammatory monocytes [11, 12], and research 
implicates these monocytes in obesity [6, 13], inflammatory conditions including 
atherosclerosis [13, 14], and cardiovascular events and endpoint (cardiovascular death, 
acute myocardial infarction or non-hemorrhagic stroke) [15, 16].  
Purposeful weight loss is an effective way for adults with excess adiposity to improve 
body composition and cardio-metabolic health outcomes [1, 17]. Importantly, 
consumption of higher amounts of protein while dieting promotes greater body fat loss 
and fat-free mass retention, which are considered positive outcomes for health [1, 18]. 
However, the impact of higher dietary protein intake on changes in the various 
monocyte subpopulations (MS) during weight loss remains unknown. 
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The purpose of this study was to assess the effect of a higher dietary protein intake 
on energy restriction-induced changes in MS and plasma lipids and lipoproteins in 
overweight and obese adults. This assessment was a secondary analysis of data from a 
study designed to investigate the effect of higher-protein intake on cardiovascular 
disease and diabetes risk factors and body composition after weight loss. Our first 
specific aim was to investigate the effect of higher dietary protein on changes in MS 
while consuming an energy restriction (ER) diet. We hypothesized that independent of 
protein intake ER-induced weight loss would decrease the cell numbers of the various 
MS. Our second specific aim was to examine the relations between the various MS and 
plasma lipids and lipoproteins. We hypothesized that the different MS and plasma lipids 
and lipoproteins would be associated with each other. Experimentally, these hypotheses 
were tested by measuring the cell numbers of the blood MS and plasma lipids and 
lipoproteins concentrations before and after these subjects completed a 16-wk 
controlled feeding intervention. 
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2. Methods and Materials 
2.1 Subjects 
Sixty-nine overweight and obese adults (body mass index (BMI) range: 25-38 kg/m2) 
were recruited from the greater Lafayette, Indiana, region, and 48 of 69 subjects 
completed the original intervention (9 discontinued the baseline and 12 discontinued the 
intervention). Among the 48 subjects, data on the MS were collected from 32 subjects 
and analyzed for this research (4 were deemed noncompliant with the original 
intervention; blood collected from 11 were not able to be analyzed due to issues with 
blood collection and shipping; and 1 provided an abnormal white blood cell number) 
(Figure 1). Inclusion criteria for this study were as follows; either male or female; aged 
35-65 y; weight stable (±3 kg) during last 3 months; no acute illness; not diabetic, 
pregnant or lactating; not currently (or within last 3 months) following an exercise or 
weight loss program; non-smoking; not lactose intolerant; natural waist circumference 
≥102 cm for male and ≥88 cm for female), blood pressure <140/90 mmHg; fasting 
serum glucose concentration <110 mg/dL; fasting serum total-cholesterol (TC) 
concentration <260 mg/dL; fasting serum low density lipoprotein cholesterol (LDL) 
concentration <160 mg/dL; fasting serum triglyceride (TG) concentration <400 mg/dL; 
and normal albumin and pre-albumin concentrations. All testing procedures were 
approved by the Purdue University Biomedical Institutional Review Board. Each subject 
signed an informed consent form and a monetary stipend was provided for participation. 
This trial was registered at clinicaltrials.gov as NCT01692860. 
 
2.2 Experimental Design 
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This experiment was a 20-wk randomized, parallel, placebo controlled, double blind, 
and prospective study (1-wk pre study measurement, 3-wk controlled feeding baseline, 
and 16-wk controlled feeding, ER intervention) design. After the 3-wk baseline period, 
subjects were randomly allocated to either a high protein (HP, n=14) or normal protein 
(NP, n=18) diet and consumed an ER diet for 16 wk. Randomization was conducted 
using the first generator (6 participants/block with separate random assignments; 10 
blocks for women and 4 blocks for men) on Randomization.com.  
 
2.3 Diet Intervention  
Total energy requirement for each subject was estimated using sex-specific 
equations for overweight and obese adults [19]. During the 3-wk baseline period, all 
subjects consumed an energy-balance diet providing 0.8 g protein•kg body mass-1•d-1 
and selected food and beverage items contained 0.7 g•kg body mass-1•d-1 of the 
carbohydrate powder maltodextrin (Muscle Feast LLC, Hebron, OH). During the 16-wk 
intervention period, subjects were randomly assigned to either the NP group (total 
protein intake 0.8 g protein•kg body mass-1•d-1) or HP group (total protein intake 1.5 g 
protein•kg body mass-1•d-1). Subjects in the NP group continued to consume selected 
food and beverage items containing maltodextrin, while subjects in the HP group 
switched to the consumption of these food and beverage items containing 0.7 g 
protein•kg body mass-1•d-1 of milk protein isolate-85 (MPI-85) (Idaho Milk Products, Inc. 
Jerome, ID). The ER (a 750 kcal energy deficit per day) was achieved by excluding non-
protein foods and beverages from each subject’s energy-balance diet menu. All 
subjects self-purchased most foods and beverages based on counseled 7-d rotating 
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menus and shopping lists, and were provided the selected foods and beverages that 
contained the maltodextrin or MPI-85 powders. Twenty-four-hour urinary urea nitrogen 
(UUN)/Creatinine ratio was assessed at wk 1, 4, 8, 12, 16, and 20 as an indicator of 
compliance to the diet, consistent with differences in total protein intake. 
 
2.4 Body Composition 
Fasting-state body mass, adjusted for clothing mass, was measured (±0.01 kg) 
using a digital platform scale (model ES200L, Ohaus Corporation, Pine Brook, NJ). 
Height (±0.1 cm) was measured from a standing body without shoes using a wall-
mounted stadiometer. BMI (kg/m2) was calculated from the collected body mass and 
height measurements. Fasting-state body mass was also measured weekly during 
baseline and the intervention period to document compliance to the ER diet. 
 
2.5 White Blood Cells, Plasma Lipids and Lipoproteins Analyses  
Fasting state blood samples were collected at the end of baseline week 3 and 
intervention week 16. Subjects arrived at the Purdue Clinical Research Center in the 
morning. Subjects then rested in a seated position for 15 min and fasting blood samples 
were drawn. Whole blood samples were aliquoted into EDTA tubes (BD Biosciences) 
and sent to Mid America Clinical Laboratory (Indianapolis, IN) for the evaluation of white 
blood cells, neutrophils, lymphocytes, monocytes, and eosinophils using flow-cytometric 
methodology and an ADVIA 2120i Hematology system (Siemens Medical Solutions 
USA, Inc., Malvern, PA). Blood samples were also aliquoted into EDTA tubes (BD 
Biosciences) and centrifuged at 4°C for 10 min at 3000 × g, and aliquots of plasma were 
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stored at −80°C until thawed for lipids and lipoproteins analyses. Plasma TC, high 
density lipoprotein cholesterol (HDL), and TG concentrations were measured in 
duplicate using an oxidase method on a COBAS analyzer (Roche Diagnostic Systems, 
Indianapolis, IN), and LDL was estimated using the Friedewald equation [20]. TC/HDL 
and LDL/HDL ratios were calculated by dividing TC and LDL by HDL, respectively. 
Additionally, 8mL of whole blood was collected into cell preparation tubes (CPT, BD 
Biosciences), with the mononuclear cells (MNCs) being isolated following a 
centrifugation at 1,600g for 30 minutes at room temperature. The MNC fraction was 
sent to the Angio BioCore located at Indiana University, Indianapolis, IN, for the 
enumeration of four MS using a 7-color multi-parametric flow cytometry (MPFC) 
protocol as previously described [21-23]. To ensure reproducibility, the MNCs were 
stained and fixed within 24 hours after initial blood collection, with fixed samples being 
run on the cytometer within 72 hours. 
 
2.6 MPFC Immunostaining, Acquisition and Analysis  
The following primary conjugated monoclonal antibodies were used: anti-human 
CD31 fluoroscein isothyocyanate (FITC, BD Pharmingen, cat. no. 555445), anti-human 
CD34 phycoerythrin (PE, BD Pharmingen, cat. no. 550761), anti-human AC133 
allophycocyanin (APC, Miltenyi Biotec cat. no. 130-090-826), anti-human CD14 
PECy5.5 (Abcam, cat. no. ab25395), anti-human CD45 APC-AlexaFluor (AF) 750 
(Invitrogen, cat. no. MHCD4527), anti-human CD16 PECy7 (BD Pharmingen, cat. no. 
557744), and the fixable amine reactive viability dye, LiveDead (Violet, Invitrogen cat. 
no. L34955). In order to resolve the cell populations of interest, specific antigen and 
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fluorochrome conjugate coupling was optimized for the six-antibody plus viability marker 
staining panel [21-23]. Both endothelial and hematopoietic stem/progenitor cells were 
evaluated as previously published [21-23]. The four MS evaluated were 
CD14dimCD16++, CD14+CD16+, CD14++CD16+, and CD14++CD16- cells.  
Blood MNCs were incubated with a proprietary Fc blocking reagent (Miltenyi Biotec 
Inc.) for 10 minutes on ice and stained as previously described [21-23]. Briefly, cells 
were incubated with titered antibodies for 30 minutes at 4˚C, washed twice in PBS with 
2% fetal bovine serum, fixed in 1% paraformaldehyde (Tousimis, Rockville, MD), and 
subsequently run on a BD LSRII flow cytometer (BD, Franklin Lakes, NJ) equipped with 
a 405nm violet laser, 488nm blue laser and 633nm red laser. Data were acquired 
uncompensated and exported as FCS 3.0 files, and analyzed utilizing FlowJo software, 
version 9.7.6 (Tree Star, Inc). “Fluorescent minus one” gating controls were also used to 
ensure proper gating of positive events [21, 22]. 
The monocytes were expressed as a percentage of the total circulating MNC 
population obtained from the MPFC analysis (Figure 2.). Absolute values of each MS 
were then calculated using the absolute monocyte numbers from the complete blood 
number results analyzed by Mid America Clinical Laboratory. 
 
2.7 Power Calculation and Statistical Analyses   
Since the assessment of changes in MS was a secondary objective of the original 
study, subject sample size estimates were not done based on this outcome of interest. 
Retrospectively, we conducted an effect-size calculation. For this parallel designed 
study, a power calculation was completed for 2 independent means to detect a 
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difference equal to 1 SD between HP and NP (a=0.05; 80% power; 2 tailed). The effect 
size was one, and the number of participants needed was 34 (n=17/group). Our sample 
size (n=32) offered us 78% actual power. 
Independent t-tests were applied to assess the differences between HP and NP 
groups for baseline subject characteristics and 24 hour UUN/Creatinine ratio. Repeated 
measures ANOVA (MIXED Procedure) were used to assess the main effects of time, 
diet, and time-by-diet interaction using age and gender as covariates. Paired t-tests 
were also used to compare differences between baseline and post-intervention. A 
multiple linear regression model was used to assess associations between the 
monocyte numbers and concentrations of plasma lipids and lipoproteins, with all 
estimates adjusted for age and gender. All statistical analyses were completed using 
SAS Version 9.2 (SAS Institute Inc. Cary, NC) and data are presented as least-square 
means±SE, unless otherwise noted. Statistical significance was determined at p<0.05 
for all analyses.  
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3. Results 
3.1 Participants’ Baseline Characteristics  
The means±SE of age, body mass, and BMI in HP (4 males and 10 females) and 
NP (5 males and 13 females) groups were as follows: 51±1.5 y, 89.3±2.8 kg, and 
31.6±1.0 kg/m2 and 52±2.0 y, 84.3±2.6 kg, and 31.1±0.6 kg/m2, respectively. No 
statistical differences were observed in these variables between the HP and NP groups. 
 
3.2 Dietary Compliance  
All subjects were compliant with the ER diet on the basis of decreased body mass 
and BMI after the 16-wk intervention period (Table 1) and gradual declines of weekly 
body mass (Figure 3). No differences were observed for 24 hour UUN/Creatinine ratio 
between HP and NP at baseline week 3, however, it was higher in HP than NP during 
the 16-wk intervention period (Figure 4). 
 
3.3 Changes in Plasma Lipids, Lipoproteins, and White Blood Cell Numbers  
From baseline week 3 to intervention week 16 (i.e. over time), TG, TC, LDL, TC/HDL 
ratio, and LDL/HDL ratio were all decreased, whereas HDL was increased in both HP 
and NP (Figure 5 and Table 1). Total numbers of white blood cells, neutrophils, 
lymphocytes, monocytes, and eosinophils remained unchanged over time (Table 1).  
 
3.4 Changes in Monocyte Numbers  
No change was observed for any of the endothelial or hematopoietic stem/progenitor 
cell populations (data not shown). However, protein intake did change the specific 
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numbers of MS throughout the study. Over time, CD14++CD16+ cell numbers 
decreased, while CD14dimCD16++, CD14+CD16+, and CD14+CD16- cell numbers 
remained unchanged, independent of protein intake (Figure 6 and Table 2). 
 
3.5 Relationship between Monocyte Numbers and Plasma Lipids and Lipoproteins 
Profiles  
Table 3 presents associations between the monocyte numbers and lipids or 
lipoproteins using data from both baseline and post-intervention. Expression of 
CD14dimCD16++ cells was shown to be negatively associated with TC and TG, but not 
with other variables. CD14+CD16+ cell expression was not associated with lipids and 
lipoproteins, whereas CD14++CD16+ cells were shown to be positively associated with 
TC, LDL, TC/HDL ratio, and LDL/HDL ratio. Additionally, no associations were observed 
between CD14++CD16- cells and lipids or lipoproteins. Over time, changes in the 
monocyte numbers were not associated with changes in lipids and lipoproteins (Table 
4).   
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4. Discussion 
Monocytes are involved in obesity-induced immune response [4-6], and mounting 
evidence suggests that specific MS that express intermediate to high levels of CD16 
(CD16+ and CD16++) are associated with obesity [6, 13] and cardiovascular events [15, 
16]. Very limited research has assessed changes in MS during weight loss [6, 24]. 
Consistent with our hypothesis, ER-induced weight loss improved CD14++CD16+ 
monocyte numbers and lipids and lipoproteins independent of dietary protein intake in 
overweight and obese adults. Our findings also confirm positive relations between 
CD14++CD16+ monocyte numbers and plasma lipids and lipoproteins.  
Weight loss may improve obesity-induced immune response by decreasing the 
monocyte numbers and pro-inflammatory cytokines [4]. Although findings from human 
intervention studies are limited, some studies particularly investigated the impact of 
various types of weight loss on changes in MS. One study observed a reduction of 
CD14+CD16+ cells after surgery-induced weight loss in obese subjects [6]. However, 
consistent with our findings, no changes in CD14+CD16+ cells were observed after 6 [6] 
to 12 [24] weeks of ER-induced weight loss. We did however observe a reduction in the 
number of CD14++CD16+ cells (known as intermediate or pro-inflammatory monocytes) 
[11, 12] after 16 weeks of ER-induced weight loss. This result may suggest that ER-
induced weight loss contributes to improving immunity by decreasing this distinct 
subpopulation of monocyte.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
While beneficial effects of HP intake on body composition and cardio-metabolic 
health during weight loss are well defined [18, 25], its impact on immune response, 
particularly during weight loss in overweight and obese adults, is unclear. Limited 
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animal research suggests sulfur-containing amino acids, methionine and cysteine, 
modulate immune responses [26]. In humans, the impact of higher dietary protein intake 
achieved by consuming either beef or chicken on innate immunity was assessed in 
obese postmenopausal women after nine weeks of ER-induced weight loss [27]. HP 
intake did not affect the majority of indices of innate immunity, including white blood cell 
numbers, consistent with our current findings.  
Interactions between MS and lipid or lipoprotein metabolism were reported in several 
in vitro studies [28, 29]. Multiple human clinical studies also observed associations 
between MS, CD16+/++ in particular, and blood lipid and lipoprotein concentrations [6, 
13, 30-32]. CD16+ monocytes were positively correlated with TC, LDL, and TG 
concentrations in hypercholesterolemic patients with coronary heart disease [30] and in 
lean to obese adults [6]. In contrast, CD16+ monocytes were negatively correlated with 
HDL concentration in lean to obese [6] and healthy [13] adults. In our study, we also 
found positive correlations between CD16+ monocytes number and lipid and lipoprotein 
concentrations in middle-aged overweight and obese adults. Collectively, higher cell 
numbers for CD16+/++ monocytes may contribute to worsened plasma lipids and 
lipoproteins profiles. However, these associations need to be interpreted with caution 
because they are not cause and effect relations.  
The novelty of this study is supported by the lack of human intervention studies 
assessing the impact of higher dietary protein intake on changes in MS during weight 
loss in overweight and obese adults applying a randomized controlled study design. 
However, we recognize that MS were analyzed from only 32 of 44 participants who 
completed the original intervention, mostly due to unexpected difficulties with blood 
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sample collection and processing. Another limitation may be that other immune-related 
cells and immune function may contribute to immune response. Thus, more research is 
needed to assess the impact of ER-induced weight loss and dietary protein intake on 
those components.  
Our experimental design included measuring outcomes of interest at baseline while 
subjects consumed an energy balance diet while the post-intervention samples were 
obtained while subjects consumed an ER diet. Thus, our experimental design does not 
allow us to distinguish between the effects of weight loss versus dietary ER on changes 
in the MS. This issue is pertinent to comparable research studies.  
In summary, ER-induced weight loss may improve immunity by partially decreasing 
the cells number of pro-inflammatory monocytes (CD14++CD16+ cell), in middle-aged, 
overweight and obese adults who consumed either normal or higher amounts of dietary 
protein. Distribution of distinct MS may also predict plasma concentrations of lipids and 
lipoproteins in these adults at risk for cardiovascular disease.  
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Table 1. Plasma lipids, lipoproteins, and white blood cell counts 
 HP pre HP post NP pre NP post 
Time effect, p Group effect, p 
Time-by-
group 
interaction, p 
Body mass (kg)  89.4 ± 2.5 80.5 ± 2.5 84.5 ± 2.2 76.5 ± 2.2 <0.0001 0.16 0.41 
BMI (kg/m
2
)  30.8 ± 0.8 27.6 ± 0.8 30.0 ± 0.7 27.0 ± 0.7 <0.0001 0.48 0.70 
Lipids and lipoproteins    
TC (mg/dL)  173.5 ± 7.2 148.1 ± 7.2 176.2 ± 6.4 159.7 ± 6.4 <0.0001 0.42 0.18 
TG (mg/dL)  136.2 ± 11.5 81.7 ± 11.5 120.7 ± 10.3 86.7 ± 10.3 <0.0001 0.67 0.23 
HDL (mg/dL)  41.7 ± 3.1 44.7 ± 3.1 44.4 ± 2.7 47.9 ± 2.7 0.004 0.44 0.77 
LDL (mg/dL)  104.5 ± 7.0 86.8 ± 7.0 107.5 ± 6.2 94.3 ± 6.2 <0.0001 0.54 0.43 
TC/HDL  4.4 ± 0.3 3.4 ± 0.3 4.2 ± 0.2 3.5 ± 0.2 <0.0001 0.86 0.14 
LDL/HDL  2.7 ± 0.2 2.0 ± 0.2 2.6 ± 0.2 2.1 ± 0.2 <0.0001 0.98 0.27 
White blood cell counts        
White blood cells (10
6
/mL) 5.83 ± 0.41 5.77 ± 0.41 6.01 ± 0.37 5.74 ± 0.37 0.29 0.88 0.50 
Neutrophils (10
6
/mL) 3.38 ± 0.35 3.34 ± 0.35 3.52 ± 0.31 3.47 ± 0.31 0.72 0.76 0.98 
Lymphocytes (10
6
/mL) 1.86 ± 0.12 1.81 ± 0.12 1.91 ± 0.11 1.70 ± 0.11 0.09 0.82 0.32 
Monocytes (10
6
/mL) 0.42 ± 0.03 0.43 ±0.03 0.39 ± 0.03 0.39 ± 0.03 0.84 0.32 0.84 
Eosinophils (10
6
/mL) 0.12 ± 0.03 0.17 ± 0.03 0.15 ± 0.03 0.16 ± 0.03 0.08 0.65 0.26 
Results are reported as lsmeans±SE. Analyses are adjusted for age and gender. HP, high protein; NP, normal protein; TC, total cholesterol; TG, 
triglyceride; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol. 
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Table 2. Monocyte subpopulation cell numbers 
 HP pre HP post NP pre NP post 
Time effect, p Group effect, p 
Time-by-group 
interaction, p 
CD14
dim
CD16
++
 
(10
6
/mL)  
0.0003 ± 0.009 0.0003 ± 0.009 0.0009 ± 0.0008 0.0026 ± 0.0008 0.30 0.09 0.28 
CD14
+
CD16
+
 
(10
6
/mL) 
0.023 ± 0.005 0.028 ± 0.005 0.023 ± 0.004 0.031 ± 0.004 0.18 0.73 0.72 
CD14
++
CD16
+
 
(10
6
/mL)  
0.016 ± 0.003 0.009 ± 0.003 0.013 ± 0.002 0.005 ± 0.002 0.0005 0.21 0.96 
CD14
++
CD16
-
 
(10
6
/mL) 
0.321 ± 0.030 0.346 ± 0.030 0.296 ± 0.027 0.291 ± 0.027 0.56 0.25 0.37 
Results are reported as lsmeans±SE. Analyses are adjusted for age and gender. HP, high protein; NP, normal protein. 
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Table 3. Associations between monocytes subpopulations and lipids and lipoproteins  
 CD14dimCD16++ (106/mL) CD14+CD16+ (106/mL) CD14++CD16+ (106/mL) CD14++CD16- (106/mL) 
 β* (95% CI) 
p β* (95% CI) p β* (95% CI) p β* (95% CI) p 
TC (mg/dL) -2153 (-4293, -14) 0.049 83 (-309, 475) 0.67 1087 (437, 1737) 0.001 30 (-37, 96) 0.38 
TG (mg/dL) -3561 (-7189, 67) 0.05 -72 (-736, 593) 0.83 607 (-582, 1796) 0.31 102 (-9, 213) 0.07 
HDL (mg/dL) 126 (-744, 996) 0.77 130 (-21, 281) 0.09 -210 (-484, 64) 0.13 -15 (-42, 11) 0.24 
LDL (mg/dL) -1546 (-3551, 458) 0.13 -41 (-404, 322) 0.82 1179 (600, 1759) < 0.001 24 (-38, 86) 0.44 
TC/HDL -67 (-147, 14) 0.11 -7 (-21, 8) 0.36 41 (16, 65) 0.001 2 (-1, 4) 0.20 
LDL/HDL -45 (-109, 19) 0.16 -6 (-17, 6) 0.32 37 (18, 55) < 0.001 1 (-1, 3) 0.28 
* Estimates of adjusted regression coefficient between monocytes and lipids and lipoproteins. All estimates are adjusted for age and 
gender. TC, total cholesterol; TG, triglyceride; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol.    
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Table 4. Associations between changes in monocytes subpopulations and changes in lipids and lipoproteins  
 Δ CD14dimCD16++ (106/mL) Δ CD14+CD16+ (106/mL) Δ CD14++CD16+ (106/mL) Δ CD14++CD16- (106/mL) 
 β* (95% CI) 
p β* (95% CI) p β* (95% CI) p β* (95% CI) p 
Δ TC (mg/dL) -403 (-1980, 1174) 0.61 231 (-19, 482) 0.07 -202 (-864, 460) 0.54 7 (-73, 87) 0.86 
Δ TG (mg/dL) 606 (-2955, 4167) 0.73 280 (-309, 869) 0.34 -222 (-1754, 1311) 0.77 60 (-123, 242) 0.51 
Δ HDL (mg/dL) -178 (-523, 167) 0.30 36 (-21, 94) 0.21 -70 (-220, 79) 0.35 -12 (-29, 6) 0.19 
Δ LDL (mg/dL) -312 (-1609, 985) 0.63 134 (-79, 346) 0.21 -72 (-623, 479) 0.79 6 (-61, 72) 0.86 
Δ TC/HDL 8 (-42, 58) 0.74 4 (-4, 12) 0.31 6 (-15, 26) 0.59 1 (-2, 3) 0.47 
Δ LDL/HDL 4 (-32, 41) 0.81 3 (-4, 9) 0.41 6 (-10, 21) 0.46 1 (-1, 2) 0.54 
* Estimates of adjusted regression coefficient between monocytes with lipid-lipoproteins. All estimates are adjusted for age and 
gender. TC, total cholesterol; TG, triglyceride; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol.   
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Figure 1. Consort flow diagram 
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Figure 2. Representative gating strategy of human monocyte populations based on CD14 
and CD16 expression 
 
High SSC monocytes (red box) are gated into a LIVEDEAD plot (green box). As monocytes 
have a higher autofluoresence, live cells are shifted to the positive decades. Live cells are gated 
for CD45 through histogram into the four monocyte populations. CD14dimCD16++ (orange 
box), CD14-CD16+ (dark blue box), CD14+CD16+ (purple box), and CD14+CD16- (light blue 
box). 
  
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
ACCEPTED MANUSCRIPT
7 
Figure 3. Change in body mass during the 16-wk intervention period 
Results are reported as means±SE. Statistical main effect of time, p<0.0001; main effect of 
group, p=0.14; time-by-group interaction, p=0.78. HP, high protein; NP, normal protein.
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Figure 4. Change in 24 hour UUN/Creatinine ratio 
Results are reported as means±SE. Values without a common letter are significantly different at 
each intervention period, p<0.05. HP, high protein; NP, normal protein; UUN, urinary urea 
nitrogen. 
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Figure 5. Changes in plasma lipids and lipoproteins  
Results are reported as lsmeans±SE. *A main effect of time (p<0.05). Analyses are adjusted for 
age and gender. HP, high protein; NP, normal protein; TC, total cholesterol; TG, triglyceride; 
HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol. 
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Figure 6. Changes in monocyte subpopulations 
Results are reported as lsmeans±SE. *A main effect of time (p<0.05). Analyses are adjusted for 
age and gender. HP, high protein; NP, normal protein. 
